Glenmark Pharma's stock rose after it said Glenmark Pharmaceuticals Inc., USA, has received final approval from the USFDA for its Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2%
Advisors remain in favour of Nifty despite its recent underperformance to the Sensex
The decline was led by index heavyweight Reliance Industries along with ITC and HDFC